✦ LIBER ✦

Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

✍ Scribed by Nardinelli, Luciana; Sanabani, Sabri Saeed; Didone, Alline; Ferreira, Patricia de Barros; Serpa, Mariana; Novaes, Mafalda Megumi Yoshinaga; Marchiani, Mariana; Ruiz, Antonio Lancha; Lima, Ismael Severino; Chamone, Dalton de Alencar Fischer

Book ID: 111875767
Publisher: S. Karger AG
Year: 2012
Tongue: English
Weight: 602 KB
Volume: 127
Category: Article
ISSN: 0001-5792
DOI: 10.1159/000336610

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of the Uptake Drug Transporte

Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia

✍ Wang, L; Giannoudis, A; Lane, S; Williamson, P; Pirmohamed, M; Clark, RE 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB

Functional polymorphisms in SOCS1 and PT

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia

✍ Vicent Guillem; Paula Amat; Francisco Cervantes; Alberto Alvarez-Larrán; Jose Ce 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 337 KB

Major molecular response to imatinib in

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

✍ Tchirkov, A; Couderc, J-L; Périssel, B; Goumy, C; Regnier, A; Uhrhammer, N; Verr 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

No significance of derivative chromosome

No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia

✍ Dong Hwan (Dennis) Kim; Gizelle Popradi; Lakshmi Sriharsha; Suzanne Kamel-Reid; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

A report of early cytogenetic response t

A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript

✍ Xiaoqing Li; Jing Yang; Xiangjun Chen; Jun Liu; Hongrui Li; Jine Zheng; Yanli He 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Adherence to the standard dose of imatin

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

✍ Chikashi Yoshida; Takuya Komeno; Mitsuo Hori; Tomofumi Kimura; Masami Fujii; Yas 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 162 KB